Oritavancin

In plain language

Oritavancin is a long-acting antibiotic for serious skin infections caused by Gram-positive bacteria, sold as Orbactiv. Its signature feature is that a full course can be one single dose.

It is a cousin of vancomycin with a fatty side chain added, which makes it last in the body for days. In trials, one infusion worked as well as a week or more of twice-daily vancomycin, a convenience that matters for patients who struggle with daily IV treatment.

For students

Oritavancin is a semi-synthetic lipoglycopeptide (about 1,793 Da) derived from chloroeremomycin, itself related to vancomycin, with a 4-chlorobenzyl substituent on the disaccharide and a fatty chain. Its dual mechanism combines D-Ala-D-Ala binding with membrane depolarization (like daptomycin) and the ability to retain activity against vanA-type resistant organisms (D-Ala-D-Lac).

Its terminal half-life of roughly 245 hours and extensive tissue binding allow a single 1,200 mg infusion for acute bacterial skin and skin-structure infections (ABSSSI). The SOLO I and SOLO II randomized trials (n=954 and 1,005) established non-inferiority to 7-10 days of twice-daily vancomycin; it also carries a labeled drug interaction consideration with unfractionated heparin (false elevation of aPTT) and warfarin monitoring requirements.

For researchers and instructors

Biochemistry. The lipoglycopeptide strategy (adding hydrophobic substituents to a glycopeptide core) dimerizes membrane binding, and oritavancin's unique chlorine-bearing arylmanosyl disaccharide is the structural lesson in engineering around vanA resistance.

Pharmacology. Single 1,200 mg 3-hour infusion; no renal or hepatic dose adjustment; heparin aPTT interference is a practical lab artifact; efficacy relies on prolonged sub-MIC exposure, making pharmacodynamic modeling central to its label.

Human evidence. SOLO I and SOLO II (combined n~1,959) showed non-inferiority to vancomycin at the 48-72 hour clinical response endpoints used in the 2013 ABSSSI guidance era.

Teaching point. The extreme case of half-life engineering: a complete antibiotic course in one infusion, and a window into how endpoint definitions (early clinical response) reshaped antibiotic approval.